Cited by 1,086SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesRespiratory viral infections research

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Open access

Gupta, Anil, Gonzalez-Rojas, Yaneicy, Juarez, Erick, Crespo Casal, Manuel, Moya, Jaynier, Falci, Diego R., Sarkis, Elias, Solis, Joel, Zheng, Hanzhe, Scott, Nicola, Cathcart, Andrea L., Hebner, Christy M., Sager, Jennifer, Mogalian, Erik, Tipple, Craig, Peppercorn, Amanda, Alexander, Elizabeth, Pang, Phillip S., Free, Almena, Brinson, Cynthia, Aldinger, Melissa, Shapiro, Adrienne E.·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2107934

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease. METHODS: In this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, nonhospitalized patients with symptomatic Covid-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression to receive a single infusion of sotrovimab at a dose of 500 mg or placebo. The primary efficacy outcome was hospitalization (for >24 hours) for any cause or death within 29 days after randomization. RESULTS: In this prespecified interim analysis, which included an intention-to-treat population of 583 patients (291 in the sotrovimab group and 292 in the placebo group), 3 patients (1%) in the sotrovimab group, as compared with 21 patients (7%) in the placebo group, had disease progression leading to hospitalization or death (relative risk reduction, 85%; 97.24% confidence interval, 44 to 96; P = 0.002). In the placebo group, 5 patients were admitted to the intensive care unit, including 1 who died by day 29. Safety was assessed in 868 patients (430 in the sotrovimab group and 438 in the placebo group). Adverse events were reported by 17% of the patients in the sotrovimab group and 19% of those in the placebo group; serious adverse events were less common with sotrovimab than with placebo (in 2% and 6% of the patients, respectively). CONCLUSIONS: Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. No safety signals were identified. (Funded by Vir Biotechnology and GlaxoSmithKline; COMET-ICE ClinicalTrials.gov number, NCT04545060.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa2107934

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study
Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., François, F., & Horwitz, L. I. (2020) · BMJ · doi:10.1136/bmj.m1966 · Cited by 3,045
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek, S. R., Boundy, E. O., Bowen, V. B., Chow, N. A., Cohn, A. C., Dowling, N. F., Ellington, S., Gierke, R., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6912e2 · Cited by 2,278
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642
Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19
Liang, W., Liang, H., Ou, L., Chen, B., Chen, A., Li, C., Li, Y., Guan, W., Sang, L., Lu, J., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.2033 · Cited by 1,387
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881

Flagged first, then by citations

Show all 25 references

Sorted by citations

Items 601–700 of 1,000

Monitoring the emergence of resistance with sotrovimab in immunocompromised patients with COVID-19: LUNAR study
Breuer, J., Drysdale, M., Walker, J. T., Han, J., Aylott, A., Dyke, M. K. V., Birch, H. J., McKie, E., Jordan, W. T., Gemzoe, K., et al. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106510 · Cited by 4
Antibody therapy reverses biological signatures of COVID-19 progression
Maher, M. C., Soriaga, L. B., Gupta, A. K., Chen, Y.-P., di Iulio, J., Ledoux, S., Smithey, M. J., Cathcart, A. L., McKusick, K., Sun, D., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100721 · Cited by 4
Self-citation
Early Treatments of Fragile Children with COVID-19—Results of CLEVER (Children COVID Early Treatment), a Retrospective, Observational Study
Minotti, C., Mengato, D., Pieri, M. D., Trivellato, S., Francavilla, A., Chiara, C. D., Liberati, C., Mattera, R., Biffi, A., Giaquinto, C., et al. (2023) · Viruses · doi:10.3390/v15010192 · Cited by 4
Use of Sotrovimab in 14 Children with COVID-19: A Single-center Experience
Butzer, S., Habbig, S., Mehler, K., Haumann, S., Meyer, M., Jung, N., & Oberthür, A. (2022) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003781 · Cited by 4
Are monoclonal antibodies effective in patients with severe obesity in SARS‐CoV‐2 infected?
Ucciferri, C., Moffa, L., Moffa, S., Vecchiet, J., & Falasca, K. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.771 · Cited by 4
A multimodal strategy to improve race/ethnic group equity in administration of neutralizing monoclonal antibody treatment for COVID-19 outpatients
Fish, L. E., Bendelow, T., Gardiner, S., Wynia, M. K., Kwan, B. M., Hamer, M. K., Ginde, A. A., & Hanratty, R. L. (2023) · Journal of Clinical and Translational Science · doi:10.1017/cts.2022.526 · Cited by 4
BMT Settings, Infection and Infection Control
Murray, J., Samarani, E., Renica, C., Agreiter, I., Orlando, L., & Hutt, D. (2023) · Springer eBooks · doi:10.1007/978-3-031-23394-4_8 · Cited by 4
COVID-19 infection in people living with HIV
Brolly, J., & Chadwick, D. (2023) · British Medical Bulletin · doi:10.1093/bmb/ldac031 · Cited by 4
Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions
Razonable, R. R. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2226326 · Cited by 4
SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges
Liu, M., Liang, Z., Cheng, Z. J., Liu, L., Liu, Q., Mai, Y., Chen, H., Lei, B., Yu, S., Chen, H., et al. (2023) · Reviews in Medical Virology · doi:10.1002/rmv.2464 · Cited by 4
Healing Treatments in COVID-19 Patients: A Narrative Review
Sixt, T., Moretto, F., Estève, C., Duong, M., Buisson, M., Mahy, S., Blot, M., & Piroth, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144672 · Cited by 4
Aptamer-Based Strategies to Address Challenges in COVID-19 Diagnosis and Treatments
Chang, Z. Y., Alhamami, F. A. M. S., & Chin, K. L. (2023) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2023/9224815 · Cited by 4
Nebulized Recombinant Tissue Plasminogen Activator (rt-PA) for Acute COVID-19-Induced Respiratory Failure: An Exploratory Proof-of-Concept Trial
Chowdary, P., Agarwal, B., Peralta, M. R., Bhagani, S. R., Lee, S., Goldring, J. J. P., Lipman, M. C. I., Waqif, E., Phillips, M., Philippou, H., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185848 · Cited by 4
Point of care detection of SARS-CoV-2 antibodies and neutralisation capacity—lateral flow immunoassay evaluation compared to commercial assay to inform potential role in therapeutic and surveillance practices
McGrath, J., O’Doherty, L., Conlon, N. P., Dunne, J., Brady, G., Ibrahim, A., McCormack, W. J., Walsh, C., Domegan, L. M., Walsh, S., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1245464 · Cited by 4
Current diagnostic and therapeutic approaches for severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) and the role of nanomaterial-based theragnosis in combating the pandemic
Zhang, B., Wu, Q., Yin, L., Jialiu, Z., Gao, W., Chen, H., & Ni, H. (2023) · Nanotechnology Reviews · doi:10.1515/ntrev-2023-0155 · Cited by 4
Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge
Chesdachai, S., Rivera, C. G., Mara, K. C., Teaford, H. R., Suarez, M. L. G., Larsen, J. J., Ganesh, R., Tulledge‐Scheitel, S. M., & Razonable, R. R. (2024) · Scientific Reports · doi:10.1038/s41598-024-56195-y · Cited by 4
Resilience to emerging infectious diseases and the importance of scientific innovation
Wilson, C., & Thomson, E. C. (2024) · Future Healthcare Journal · doi:10.1016/j.fhj.2024.100023 · Cited by 4
Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS‐CoV‐2
Richier, Q., Valence, B. D., Chopin, D., Gras, E., Levi, L. I., Aad, Y. A., Pacanowski, J., Meynard, J., Plaçais, L., Fey, D., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13272 · Cited by 4
The AIFELL Score as a Predictor of Coronavirus Disease 2019 (COVID-19) Severity and Progression in Hospitalized Patients
Levenfus, I., Ullmann, E., Petrowski, K., Rose, J., Huber, L. C., Stüssi‐Helbling, M., & Schuurmans, M. M. (2022) · Diagnostics · doi:10.3390/diagnostics12030604 · Cited by 4
Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection
Gupta, I., & Perez, E. S. A. (2022) · Cureus · doi:10.7759/cureus.22658 · Cited by 4
Predictors for Early and Late Death in Adult Patients with COVID-19: A Cohort Study
Yen, Y., Chan, S.-Y., Chen, C.-C., & Deng, C.-Y. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19063357 · Cited by 4
Evolution of Clinical Care in COVID-Infected Solid Organ Transplant Recipients
Sigler, R., Chen, V., & Law, N. (2022) · Current Transplantation Reports · doi:10.1007/s40472-022-00368-z · Cited by 4
A national survey of early treatment seeking behavior among those with incident SARS-CoV-2 infection
Kojima, N., Brobeck, M., Slepnev, V. I., & Klausner, J. D. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100934 · Cited by 4
Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants
Tang, H., Ke, Y., Wang, L., Wu, M., Sun, T., & Zhu, J. (2022) · Pharmaceuticals · doi:10.3390/ph15081002 · Cited by 4
Safety and efficacy of Siddha management as adjuvant care for COVID-19 patients admitted in a tertiary care hospital - An open-label, proof-of-concept Randomized Controlled Trial
Christian, G. J., Meenakumari, R., Shanthimalar, R., Ganesan, S., Ravichandran, V. M., Elansekaran, S., Murugan, R., Srinivasan, V. C., Elumalai, R., Kangusamy, B., et al. (2023) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2023.100706 · Cited by 4
Interleukin-62/lymphocyte as a proposed predictive index for COVID-19 patients treated with monoclonal antibodies
Rotundo, S., Borelli, M., Scaglione, V., Lionello, R., Biamonte, F., Olivadese, V., Quirino, A., Morrone, H. L., Matera, G., Costanzo, F. S., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01081-6 · Cited by 4
Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial
Saito, S., Kutsuna, S., Imamura, A., Hase, R., Oda, R., Terada-Hirashima, J., Shimizu, Y., Uemura, Y., Takamatsu, Y., Yasuhara, A., et al. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.05.012 · Cited by 4
COVID-19 in Older Adults- A Practical Review for Emergency Providers in 2022
Malone, M. L., Hogan, T. M., Bonner, A., Biese, K., Pagel, P., & Unroe, K. T. (2022) · Journal of Geriatric Emergency Medicine · doi:10.17294/2694-4715.1026 · Cited by 4
Is SARS‐CoV‐2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody‐based therapeutics?
Focosi, D., Franchini, M., Pirofski, L., Maggi, F., & Casadevall, A. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2314 · Cited by 4
Evidence-Based Recommendations on the Use of Anti-SARS-CoV-2 Monoclonal Antibodies (Casirivimab + Imdevimab, and Sotrovimab) for Adults in Ontario
Bailey, J. J., Morris, A. M., Bean, S., Cohen, E., Gubbay, J. B., Lunsky, Y., PATEL, S. N., Tran, V., Miller, K. J., Abdurrahman, Z. B., et al. (2021) · doi:10.47326/ocsat.2021.02.45.2.0 · Cited by 4
Safety and efficacy of anti-SARS-CoV-2 monoclonal antibodies in pregnancy
Buonomo, A. R., Esposito, N. D. P., Filippo, I. D., Saccone, G., Pinchera, B., Scotto, R., Bifulco, G., & Gentile, I. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2122436 · Cited by 4
Reply to “successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients—A Czech multicenter experience”: A case series of SARS‐CoV‐2 Omicron infection and aggressive lymphoma in the Sotrovimab era
Cassin, R., Rampi, N., Fidanza, C. A., Muscatello, A., Mariani, B., Noto, A., Rossi, F. G., & Baldini, L. (2022) · Hematological Oncology · doi:10.1002/hon.3079 · Cited by 4
Effectiveness of Sotrovimab in Preventing COVID-19-related Hospitalizations or Deaths Among U.S. VeteransPreprint
Young‐Xu, Y., Korves, C., Zwain, G., Satram, S., Drysdale, M., Reyes, C. M., Cheng, M. M., Epstein, L. H., Marconi, V. C., & Ginde, A. A. (2022) · medRxiv · doi:10.1101/2022.12.30.22284063 · Cited by 4
Home-First or Hospital-First? A Propensity Score–Weighted Retrospective Cohort Study
Ko, S. Q., Cheng, G. S., Teng, T. Y., & Goh, J. (2024) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2024.105154 · Cited by 3
Application of nanoparticles in antibody drug delivery
Xiefukaiti, W., Zhu, Q., Dolkun, N., & Xiao, X. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1759915 · Cited by 3
Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from dual-antigen-specific B cells from convalescents
Takeshita, M., Fukuyama, H., Kamada, K., Matsumoto, T., Makino‐Okamura, C., Lin, Q., Sakuma, M., Kawahara, E., Yamazaki, I., Uchikubo‐Kamo, T., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106955 · Cited by 3
Safety, Tolerability, Bioavailability, and Biological Activity of Inhaled Interferon-α2b in Healthy Adults: The IN2COVID Phase I Randomized Trial
Garcia‐Huidobro, D., Iturriaga, C., Pérez‐Mateluna, G., Fajuri, P., Severino, N., Urzua, M. D., Fraga, J. P., de la Cruz, J., Poli, M. C., Castro-Rodríguez, J. A., et al. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01278-3 · Cited by 3
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C)
Bell, C. F., Bobbili, P. J., Desai, R. A., Gibbons, D. C., Drysdale, M., DerSarkissian, M., Patel, V., Birch, H. J., Lloyd, E. J., Zhang, A., et al. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01344-4 · Cited by 3
Identification of an IGHV3-53-Encoded RBD-Targeting Cross-Neutralizing Antibody from an Early COVID-19 Convalescent
Hu, Y., Hu, C., Wang, S., Ren, L., Hao, Y., Wang, Z., Liu, Y., Su, J., Zhu, B., Li, D., et al. (2024) · Pathogens · doi:10.3390/pathogens13040272 · Cited by 3
Evaluation of T Cell Response to SARS-CoV-2 in Kidney Transplant Recipients Receiving Monoclonal Antibody Prophylaxis and the Utility of a Bivalent mRNA Vaccine Booster Dose
Bertrand, D., Laurent, C., Lemoine, M., Lebourg, L., Hanoy, M., Roy, F. L., Nezam, D., Pruteanu, D., Grangé, S., de Nattes, T., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12040722 · Cited by 3
Prospective clinical performance of CoVarScan in identifying SARS-CoV-2 Omicron subvariants
ZHU, K. Y., Sah, M. K., Mahimainathan, L., Liu, Y., Xing, C., Roush, K., Clark, A., & SoRelle, J. A. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.01385-24 · Cited by 3
Real-World Effectiveness of Sotrovimab in Ambulatory Patients With COVID-19: A Retrospective Cohort Study Using a Large Administrative Claims Database in the United States
Bell, C. F., Lokhandwala, T., Gibbons, D. C., Drysdale, M., Wang, J., & Lloyd, E. J. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.01.003 · Cited by 3
A Rapid Systematic Review of U.S. Food and Drug Administration-Authorized COVID-19 Treatments
Maglione, M., Klausner, J. D., Wirnkar, P. K., Fallarme, I., Lak, R., Sysawang, K. A., Fu, N., Yagyu, S., Motala, A., Tolentino, D. M., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf097 · Cited by 3
Moloney Murine Leukemia Virus-like Nanoparticles Pseudo-Typed with SARS-CoV-2 RBD for Vaccination Against COVID-19
Kratzer, B., Gattinger, P., Tauber, P. A., Schaar, M., Sehgal, A. N. A., Kraus, A., Trapin, D., Valenta, R., & Pickl, W. F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136462 · Cited by 3
Organ transplant patients, COVID‐19, and neutralizing monoclonal antibodies: The glass is half full
Angarone, M., Kumar, R. N., & Stosor, V. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13724 · Cited by 3
A strategy to optimize the peptide-based inhibitors against different mutants of the spike protein of SARS-CoV-2
Priya, P., Basit, A., & Bandyopadhyay, P. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2103587 · Cited by 3
Usage and Awareness of Antiviral Medications for Coronavirus Disease 2019 (COVID-19) Among Individuals at Risk for Severe COVID-19, March 2021 to 1 August 2022
Kojima, N., & Klausner, J. D. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac743 · Cited by 3
Better design leads to better results – Importance of virological outcome design in clinical trials for antiviral treatment of coronavirus disease 2019
Zhaori, G., Lu, L., Liu, C., Han, S., & Guo, Y. (2023) · Pediatric Investigation · doi:10.1002/ped4.12363 · Cited by 3
Cross-Reactivity of Antibodies in Intravenous Immunoglobulin Preparation for Protection against SARS-CoV-2
Osaka, T., Yamamoto, Y., Takehisa, S. O. M. A., Yanagisawa, N., & Nagata, S. (2023) · Microorganisms · doi:10.3390/microorganisms11020471 · Cited by 3
Monoclonal Antibodies in Hospitalised Patients with COVID-19: The Role of SARS-COV-2 Serostatus in an Evolving Pandemic
Raffi, F., & Gottlieb, R. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00769-2 · Cited by 3
Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron
Kreye, J., Reincke, S. M., Edelburg, S., Jeworowski, L. M., Kornau, H., Trimpert, J., Hombach, P., Halbe, S., Nölle, V., Meyer, M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106323 · Cited by 3
Ischaemic Stroke Occurring in a Patient Treated with Monoclonal Antibodies for COVID-19
Lobasso, A., di Gennaro, C., Poggiano, M. R., Vasta, A., Ranucci, R. A. N., Lobianco, R., Tucci, A. G., Cavaglià, E., & Micco, P. D. (2023) · Viruses · doi:10.3390/v15061235 · Cited by 3
SARS‐CoV‐2 spike codon mutations and risk of hospitalization after antispike monoclonal antibody therapy in solid organ transplant recipients
Yetmar, Z. A., Yao, J. D. C., & Razonable, R. R. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28885 · Cited by 3
Use of Neutralizing Monoclonal Antibodies and Its Outcome Measures in COVID-19 Patients
Chowdhury, M., Humayra, S., Sulayman, T., Mihara, K., & Rajesh, P. (2023) · Journal of Angiotherapy · doi:10.25163/angiotherapy.716324 · Cited by 3
The insights from SARS-CoV-2 antibody treatment for future emerging infectious diseases
Wang, Y., & Cao, B. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00454-1 · Cited by 3
Virus evolution and reduced viral viability during treatment of persistent COVID-19 Omicron BA.5 infection in an immunocompromised host
Kaya, H., Tani, H., Inasaki, N., Yazawa, S., Itamochi, M., Higashi, D., Tsuji, N., Nakamura, M., & Oishi, K. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.09.010 · Cited by 3
Discovery of neutralizing SARS-CoV-2 antibodies enriched in a unique antigen specific B cell cluster
Nielsen, S. S. F., Barnkob, N. M., Hansen, R. W., Bansia, H., Vestergaard, M., Rothemejer, F. H., Worsaae, A., Brown, D., Pedersen, M. L., Rahimic, A. H. F., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291131 · Cited by 3
Cell-based passive immunization for protection against SARS-CoV-2 infection
Sawula, E., Miersch, S., Jong, E. D., Li, C., Chou, F.-Y., Tang, J. K., Saberianfar, R., Harding, J. S., Sidhu, S. S., & Nagy, A. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03556-5 · Cited by 3
Passive antibody therapy in emerging infectious diseases
Yang, X. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1021-y · Cited by 3
Clinical and immunological outcomes of SARS-CoV-2-infected vaccine responders, vaccine non-responders, and unvaccinated patients evaluated for neutralizing monoclonal antibody treatment at a single German tertiary care center: a retrospective cohort study with prospective follow-up
Triebelhorn, J., Schneider, J., Spinner, C. D., Iakoubov, R., Voit, F., Wagner, L., Erber, J., Rothe, K., Berthele, A., Pernpeintner, V., et al. (2024) · Infection · doi:10.1007/s15010-023-02171-z · Cited by 3
Strategies for prevention and treatment of SARS-COV-2 infection in patients with chronic kidney disease: Literature review
Marqués, M., Múñez, E., Quiroga, B., Montejano, R., Morales, E., & Candel, F. J. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.03.010 · Cited by 3
An overview of the development of pharmacotherapeutics targeting SARS-CoV-2
Lucaj, T., Hay, I., Samarbakhsh, A., Bedi, M. F., Iyer, A. K., & Gavande, N. S. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104126 · Cited by 3
Development of a metabolome-based respiratory infection prognostic during COVID-19 arrival
Robinson, J. I., Marks, L. R., Hinton, A. L., O’Halloran, J. A., Goss, C. W., Mucha, P. J., & Henderson, J. P. (2024) · mBio · doi:10.1128/mbio.03343-23 · Cited by 3
Immunobiology and immunotherapy of COVID-19
Lundstrom, K. H. (2025) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.12.002 · Cited by 3
Review of studies on SARS-CoV-2 infection inhibitors
Michalski, A., Wójcicka, P., Bielawska-Drózd, A., & Bartoszcze, M. (2021) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/143035 · Cited by 3
Omicron: The tsunami??
Patil, B. (2022) · Indian Journal of Health Sciences and Biomedical Research (KLEU) · doi:10.4103/kleuhsj.kleuhsj_76_22 · Cited by 3
Effectiveness of Corticosteroid Therapy for Non-Severe COVID-19 in Patients Not Requiring Supplemental Oxygen Who Have Risk Factors for Severe Disease
Tanaka, T., Saito, Y., Kashiwada, T., Nakamichi, S., Matsumoto, M., Miyanaga, A., Tanaka, Y., Fujita, K., Seike, M., & Gemma, A. (2022) · Journal of Nippon Medical School · doi:10.1272/jnms.jnms.2022_89-409 · Cited by 3
Implementing Early Phase Treatments for COVID-19 in Outpatient Settings: Challenges at a Tertiary Care Center in Italy and Future Outlooks
Manciulli, T., Lagi, F., Barbiero, A., Fognani, M., Lauria, N. D., Malcontenti, C., Fiorelli, C., Spinicci, M., Ceccherini, V., D’Onofrio, P., et al. (2022) · Infectious Disease Reports · doi:10.3390/idr14030037 · Cited by 3
Clinical course of patients with severe COVID-19 pneumonia treated with remdesivir: A real-life study
Tejada, D., Juanbeltz, R., Rivero, M., Miguel, R. S., Capdevila, F., Beloqui, J. J., & Carricas, M. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267283 · Cited by 3
Development and external validation of a deep learning-based computed tomography classification system for COVID-19
Kataoka, Y., Baba, T., Ikenoue, T., Matsuoka, Y., Matsumoto, J., Kumasawa, J., Tochitani, K., Funakoshi, H., Hosoda, T., Kugimiya, A., et al. (2022) · Annals of Clinical Epidemiology · doi:10.37737/ace.22014 · Cited by 3
Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases
Mambelli, E., Gasperoni, L., Maldini, L., Biagetti, C., & Rigotti, A. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01449-z · Cited by 3
Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial
Boesing, M., Abig, K., Brändle, M., Brutsche, M. H., Burri, E., Frye, B. C., Giezendanner, S., Grutters, J. C., Haas, P., Heisler, J., et al. (2022) · Trials · doi:10.1186/s13063-022-06723-w · Cited by 3
Safety and effectiveness of RBD-specific polyclonal equine F(ab´)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study
Salazar, D. H. F., Achinelli, F., Colonna, M., Pérez, L., Giménez, A. A., Ojeda, M. A., Puente, S. N. M., Negrette, L. S., Cañete, F., Ibarra, O. I. M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274796 · Cited by 3
A practical update on the management of patients with COVID–19
Mehta, M., Navarra, A., & Mogal, R. J. (2022) · Clinical Medicine · doi:10.7861/clinmed.2022-0080 · Cited by 3
Fluid restriction management in the treatment of COVID-19: a single-center observational study
Matsumura, Y., Sugiyama, T., Kondo, N., Miyahara, M., Hanaoka, N., Nagashima, H., Kasahara, Y., Fujiyoshi, N., Inada, A., & Inaba, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-22389-5 · Cited by 3
A Review of Potential Therapeutic Strategies for COVID-19
Meng, J., Li, R., Zhang, Z., Wang, J., Huang, Q., Nie, D., Fan, K., Guo, W., Zhao, Z., & Han, Z. (2022) · Viruses · doi:10.3390/v14112346 · Cited by 3
Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients
Douin, D. J., Wogu, A. F., Beaty, L. E., Carlson, N. E., Bennett, T. D., Aggarwal, N. R., Mayer, D. A., Ong, T. C., Russell, S., Steele, J., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07819-z · Cited by 3
Antiviral Treatment of Coronavirus Disease-2019 Pneumonia
Radcliffe, C. V., Malinis, M. F., & Azar, M. M. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.11.008 · Cited by 6
Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events
Yoshida, J., Shiraishi, K., & Tanaka, M. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07889-z · Cited by 3
Serious Infusion Reactions in Two Adolescents Receiving Bebtelovimab
Peters, M. E., Strayer, J. R., & Wald, E. R. (2022) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003743 · Cited by 3
Assessment of the pneumonia severity score in community-acquired and nursing and healthcare-associated pneumonia due to COVID-19
Miyashita, N., Nakamori, Y., Ogata, M., Fukuda, N., Yamura, A., & Ishiura, Y. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.12.007 · Cited by 3
The efficacy of medicinal products based on plasma immunoglobulins and monoclonal antibodies for the treatment and prevention of COVID-19
Алексеевич, С. А., Авдеева, Ж. И., Витальевич, Г. Д., Khantimirova, L. M., Paramonova, Y. S., Smolina, E. M., Бондарев, В. П., & Меркулов, В. А. (2022) · Immunologiya · doi:10.33029/0206-4952-2022-43-5-485-503 · Cited by 3
Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score
Johnson, P. W., Kunze, K. L., Senefeld, J. W., FRÍAS, J. S. D., Isha, S., Satashia, P. H., Bhakta, S., Cowart, J. B., Bosch, W., O’Horo, J. C., et al. (2023) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2022.12.007 · Cited by 3
Risk of Underlying Diseases and Effectiveness of Drugs on COVID-19 Inpatients Assessed Using Medical Claims in Japan: Retrospective Observational Study
Mitsushima, S., Horiguchi, H., & Taniguchi, K. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s394413 · Cited by 3
Restrictions on Movement
Bennett, B., Freckelton, I. R., & Wolf, G. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192896742.003.0004 · Cited by 3
Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional centre in the UK
Goodwin, A. T., Thompson, J., & Hall, I. P. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281915 · Cited by 3
Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry
Wyszynski, D. F., Demetriou, L., Renz, C. L., Aliabadi, S., Rafailovic, D., SHULMAN, L. P., Drysdale, M., & Wurst, K. (2024) · Drug Safety · doi:10.1007/s40264-024-01439-z · Cited by 3
High mortality in patients with active malignancy and severe COVID-19
Udovica, S., Müser, N., Pechlaner, A., Reichinger, A., Aichinger, C., Strasser‐Weippl, K., Rumpold, H. F., Petzer, A. L., Wöll, E., Hilbe, W., et al. (2022) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-022-00814-9 · Cited by 3
Clinical course of patients with chronic limb-threatening ischemia developing COVID-19
Ishihara, T., Iida, O., Takahara, M., Tsujimura, T., Higashino, N., Hata, Y., Toyoshima, T., Nakao, S., & Mano, T. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.07.010 · Cited by 3
Clinical Impact of Monoclonal Antibodies in the Treatment of High-Risk Patients with SARS-CoV-2 Breakthrough Infections: The ORCHESTRA Prospective Cohort Study
Savoldi, A., Morra, M., Castelli, A., Mirandola, M., Berkell, M., Smet, M., Konnova, A., Rossi, E., Cataudella, S., Nardo, P. D., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092063 · Cited by 3
Self-citation
Management of COVID-19: A comprehensive and practical approach
Barthwal, M. S., Dole, S. S., & Sahasrabudhe, T. R. (2022) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2022.06.020 · Cited by 3
Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience
Moriello, N. S., Buonomo, A. R., Scotto, R., Pinchera, B., Sarno, M., Fusco, L., Viceconte, G., Iuliano, A., Zappulo, E., Foggia, M., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13126 · Cited by 3
Electrocardiographic Pathological Findings Caused by the SARS-CoV-2 Virus Infection: Evidence from a Retrospective Multicenter International Cohort Longitudinal Pilot Study of 548 Subjects
Susca, N., Solimando, A. G., Borrelli, P., Marziliano, D., Monitillo, F., Raimondo, P., Vestito, D., Lopizzo, A., Brindicci, G., Abumayyaleh, M., et al. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10020058 · Cited by 3
A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma
Suzuki, T., Kusumoto, S., Kamezaki, Y., Hashimoto, H., Nishitarumizu, N., Nakanishi, Y., Kato, Y., Kawai, A., Matsunaga, N., Ebina, T., et al. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03550-w · Cited by 3
Evidence-Based Recommendations on the Use of Casirivimab + Imdevimab, and Sotrovimab for Adults in Ontario
Bailey, J. J., Morris, A. M., Bean, S., Cohen, E., Gubbay, J. B., Lunsky, Y., Patel, S. H., Tran, V., Miller, K. J., Abdurrahman, Z. B., et al. (2021) · doi:10.47326/ocsat.2021.02.45.1.0 · Cited by 3
Early Treatment with Sotrovimab for Covid-19
Hatzl, S., Krause, R., & Schilcher, G. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2201606 · Cited by 3
Impact of COVID-19 Infection on Lung Transplantation Management
Gil, M. P. U. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2022.03.004 · Cited by 3
Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 TrialPreprint
Holland, T. L., Ginde, A. A., Paredes, R., Murray, T. A., Engen, N. W., Grandits, G., Vekstein, A. M., Ivey, N., Mourad, A., Sandkovsky, U., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4087355 · Cited by 3
In silico evaluation of anti SARS-CoV-2 antibodies neutralization power: A blueprint with monoclonal antibody SotrovimabPreprint
Ashoor, D., Marzouq, M., & Fathallah, M. D. (2023) · Research Square · doi:10.21203/rs.3.rs-2696333/v1 · Cited by 3
Managing COVID-19 in pregnant women
Teelucksingh, S., Nana, M., & Nelson‐Piercy, C. (2022) · Breathe · doi:10.1183/20734735.0019-2022 · Cited by 2

Authors: Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., Cathcart, A. L., Hebner, C. M., Sager, J., Mogalian, E., Tipple, C., Peppercorn, A., Alexander, E., Pang, P. S., Free, A., Brinson, C., Aldinger, M., & Shapiro, A. E.
Affiliations: William Osler Health System (CA)
From the Albion Finch Medical Centre, William Osler Health Centre, Toronto (A.G.); Optimus U (Y.G.-R.) and Florida International Medical Research (E.J.), Miami, Pines Care Research Center, Pembroke Pines (J.M.), and Sarkis Clinical Trials, Gainesville (E.S.) — all in Florida; Álvaro Cunqueiro Hospital, IIS Galicia Sur, Vigo, Spain (M.C.C.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (D.R.F.); Centex Studies, McAllen (J. Solis), and Central Texas Clinical Research, Austin (C.B.) — both in Texas; Vir Biotechnology, San Francisco (H.Z., A.L.C., C.M.H., J. Sager, E.M., E.A., P.S.P., M.A.); GlaxoSmithKline, Stevenage, United Kingdom (N.S., C.T.); GlaxoSmithKline, Cambridge, MA (A.P.); Pinnacle Research Group, Anniston, AL (A.F.); and the Departments of Global Health and Medicine, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle (A.E.S.).
Hospital de Clínicas de Porto Alegre (BR)
The University of Texas at Austin (US)
VIR Biotechnology (United States) (US)
GlaxoSmithKline (United Kingdom) (GB)
GlaxoSmithKline (United States) (US)
University of Washington (US)
Corresponding author: Shapiro, Adrienne E.
ORCID: Pang, Phillip S.
Shapiro, Adrienne E.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-11-18
Volume: 385
Issue: 21
Pages: 1941-1950
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2107934
OpenAlex: W3208080692
Cited by: 1,086
References: 25
Citations by year: 2026: 25 · 2025: 72 · 2024: 119 · 2023: 294 · 2022: 509 · 2021: 62
FWCI: 78.13
Type: journal article
Language: en
Open access: green
doi.org
Licence: cc-by-nc-nd
www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
medRxiv (acceptedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Vir Biotechnology, Inc., in collaboration with GlaxoSmithKline
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords: sotrovimab, COVID-19 pandemic, SARS-CoV-2, neutralizing monoclonal antibodies, early treatment, disease progression, hospitalization, mortality, high-risk patients, non-hospitalized patients, presymptomatic treatment, adverse events
MeSH terms: SARS-CoV-2, COVID-19 Drug Treatment, Adult, Aged, Ambulatory Care, Double-Blind Method, Female, Hospitalization, Humans, Infusions, Intravenous, Length of Stay, Male, Middle Aged, Incidence, Disease Progression, Antibodies, Neutralizing, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks